Tonsillectomy, high dose immunoglobulins, and cyclophosphamide in progressive IgA-nephropathy

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• IgA-nephropathy (IgAN) is a progressive kidney disease with no established effective therapies.
• Advanced IgAN presents significant risks for end-stage renal failure.

Purpose of the Study:

• To evaluate the efficacy of different treatment modalities in patients with progressive IgA-nephropathy.
• To identify predictors of renal function decline in IgAN.
• To compare treatment outcomes against historical untreated controls.

Main Methods:

• Retrospective analysis of 40 patients with progressive IgAN treated with tonsillectomy/cyclophosphamide (TE/CTX), intravenous immunoglobulin (IVIG), or cyclophosphamide pulses (CyP).
• Comparison with 8 untreated historical controls.
• Statistical analysis including Cox regression, linear regression, and Kaplan Meier survival analysis.

Main Results:

• Cyclophosphamide pulses (CyP) significantly reduced the annual decline in renal function from 29.7% to 2.8%.
• CyP therapy also led to a significant decrease in proteinuria from 1.3 g/l to 1.1 g/l.
• Tonsillectomy/cyclophosphamide (TE/CTX) and IVIG did not demonstrate significant long-term benefits on renal function.
• Serum creatinine >250 micromol/l, proteinuria >2.5 g/l, and age >51 years predicted end-stage renal failure.

Conclusions:

• Cyclophosphamide pulses (CyP) therapy is effective in halting renal function loss and reducing proteinuria in progressive IgA-nephropathy.
• Tonsillectomy/cyclophosphamide (TE/CTX) is not recommended for advanced progressive IgAN unless surgically indicated.
• Intravenous immunoglobulin (IVIG) lacks sustained long-term efficacy for IgAN progression.